AmoyDx(SZ:300685) Sou Hu Cai Jing·2025-07-29 09:40Core Viewpoint - The company, Adicon Biological, has reported a decline in stock price and a relatively low price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation despite strong revenue and profit growth [1][2]. Group 1: Company Performance - On July 29, Adicon Biological's stock closed at 23.87 yuan, down 2.77%, with a rolling PE ratio of 31.15 times and a total market capitalization of 9.346 billion yuan [1]. - For the first half of 2025, the company achieved operating revenue of 579 million yuan, a year-on-year increase of 6.69%, and a net profit of 189 million yuan, reflecting a year-on-year growth of 31.41% with a sales gross margin of 84.00% [2]. Group 2: Industry Comparison - The average PE ratio for the medical device industry is 55.46 times, with a median of 37.74 times, positioning Adicon Biological at 62nd place within the industry [1]. - The company’s PE ratio is significantly lower than the industry average, suggesting it may be undervalued compared to its peers [2]. Group 3: Company Background and Achievements - Adicon Biological specializes in tumor gene testing reagents, software, and supporting instruments, along with providing testing services and drug clinical research services [1]. - The company has received multiple national and industry honors, including "National High-tech Enterprise" and "National Enterprise Technology Center," highlighting its achievements in technology innovation [1].